MyoKardia Inc. (MYOK)’s Financial Results Comparing With ObsEva SA (NASDAQ:OBSV)

MyoKardia Inc. (NASDAQ:MYOK) and ObsEva SA (NASDAQ:OBSV) compete against each other in the Biotechnology sector. We will compare them and contrast their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MyoKardia Inc. 51 115.29 N/A -2.20 0.00
ObsEva SA 12 31888.87 N/A -1.97 0.00

Demonstrates MyoKardia Inc. and ObsEva SA earnings per share, top-line revenue and valuation.


Table 2 represents MyoKardia Inc. (NASDAQ:MYOK) and ObsEva SA (NASDAQ:OBSV)’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
MyoKardia Inc. 0.00% -20% -18.3%
ObsEva SA 0.00% -53.9% -48%


18 and 18 are the respective Current Ratio and a Quick Ratio of MyoKardia Inc. Its rival ObsEva SA’s Current and Quick Ratios are 6.7 and 6.7 respectively. MyoKardia Inc. has a better chance of clearing its pay short and long-term debts than ObsEva SA.

Analyst Recommendations

In next table is delivered MyoKardia Inc. and ObsEva SA’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
MyoKardia Inc. 0 0 1 3.00
ObsEva SA 0 0 0 0.00

MyoKardia Inc.’s upside potential currently stands at 66.76% and an $90 consensus target price.

Insider and Institutional Ownership

MyoKardia Inc. and ObsEva SA has shares held by institutional investors as follows: 82.09% and 70.4%. Insiders held roughly 0.4% of MyoKardia Inc.’s shares. Comparatively, ObsEva SA has 14.47% of it’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
MyoKardia Inc. 0.09% 8.32% 15.46% 29.32% 0.15% 11.4%
ObsEva SA -10.99% -19.59% -36.38% -27.56% -33.56% -28.99%

For the past year MyoKardia Inc. has 11.4% stronger performance while ObsEva SA has -28.99% weaker performance.


MyoKardia Inc. beats ObsEva SA on 6 of the 8 factors.

MyoKardia, Inc., a clinical stage biopharmaceutical company, engages in discovering, developing, and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is MYK-461, an orally-administered small molecule that is in Phase II clinical trials designed to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy (HCM). The company also develops MYK-491, an orally-administered small molecule that treats genetic dilated cardiomyopathy (DCM) by restoring normal contractility in the diseased DCM heart. In addition, it develops HCM-2, a product candidate to reduce cardiac muscle contractility to normal levels in HCM patients; DCM-2, a product candidate that is intended to increase cardiac muscle contractility to normal levels in genetic DCM patients through a different mechanism than that of MYK-491; and LUS-1, a product candidate, which is intended to counteract a muscle disruption that results in impaired relaxation of the heart. The company has a strategic collaboration with Sanofi S.A. for the research, development, and commercialization of pharmaceutical products to treat, prevent, and diagnose HCM and DCM, as well as additional indications. MyoKardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California.

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. The company intends to develop products for treating endometriosis, uterine fibroids, and preterm labor, as well as for enhancing clinical pregnancy and live birth rates in women undergoing IVF. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to improve clinical pregnancy and live birth rates in women undergoing IVF; and OBE022, an oral and selective prostaglandin F2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of pregnancy. The company was founded in 2012 and is headquartered in Plan-les-Ouates, Switzerland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.